The DOI matches its Crossref record.
Apolipoprotein E, ɛ4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region
Abstract
An association between the 19q13.2 chromosomal region and Alzheimer's disease (AD) has been reported in AD families and for sporadic AD. Recent observations provide evidence that the ɛ4 allele of the apolipoprotein E gene (APOE), located in this region, is a risk factor for late-onset AD. Within this region, other genes possibly involved in the pathophyslology of AD and in strong linkage disequilibrium with the APOE locus may be responsible for this association. To test this hypothesis, we analysed the allelic distribution of four polymorphic genetic markers flanking the APOE gene (D19S178 (CA)n repeat, D19S47 (CA)n repeat, APOCI Hpal restriction fragment length polymorphism, APOCII (CA)n repeat). We performed these analyses in a sample of late-onset sporadic cases (n = 36) versus controls (n = 38), and in a sample of early-onset sporadic cases (n = 34) versus controls (n = 36). Early-onset cases were analysed for two cut-offs with late-onset: less than 60 and less than 65. We observed a significant increased frequency of the APOE ɛ4 allele in late-onset and early-onset AD with ages at onset less than 60 and less than 65. The adjusted odds ratio (OR) of the bearers of at least one APOE ɛ4 allele was 4.10 ([1.84; 9.16]) when estimated in both populations with a logistic regression model. Surprisingly, the odds ratio of the bearers of at least one APOE ɛ2 allele was also significant and equal to 0.11 ([0.02; 0.50]) suggesting a possible protective effect. An association with the disease was also observed for the long alleles of APOCII (CA)n repeat in the late-onset AD (OR = 3.56, [1.19; 10.70]), and for the short alleles of D19S178 (CA)n repeat In the early-onset AD (OR = 4.44, [1.27; 15.49]). In conclusion, APOE is a major risk factor for early- and late-onset sporadic AD. The combination of the APOE polymorphism with flanking markers located within the APOE locus significantly Improved the association with the disease in both populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Self-citationApolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Petersen, R. C. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520400044042 · Cited by 780
Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan
Tang, M.-X., Cross, P., Andrews, H., Jacobs, D. M., Small, S., Bell, K., Merchant, C., Lantigua, R., Costa, R., Stern, Y., et al. (2001) · Neurology · doi:10.1212/wnl.56.1.49 · Cited by 722
Berg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608
At the interface of sensory and motor dysfunctions and Alzheimer’s disease.
Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A. L., Buchman, A. S., Cruickshanks, K. J., Devanand, D. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.514 · Cited by 589
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Belloy, M. E., Napolioni, V., & Greicius, M. D. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.056 · Cited by 570
On the path to 2025: understanding the Alzheimer’s disease continuum
Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556
Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury
Nicoll, J. A. R., Roberts, G. W., & Graham, D. I. (1995) · Nature Medicine · doi:10.1038/nm0295-135 · Cited by 486
A Hundred Years of Alzheimer's Disease Research
Hardy, J. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.016 · Cited by 467
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Fullerton, S. M., Clark, A. G., Weiss, K. M., Nickerson, D. A., Taylor, S. L., Stengård, J. H., Salomaa, V., Vartiainen, E., Perola, M., Boerwinkle, E., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/303070 · Cited by 432
The chemistry of Alzheimer’s disease
Rauk, A. (2009) · Chemical Society Reviews · doi:10.1039/b807980n · Cited by 417
ALZHEIMER'S DISEASE: Genetic Studies and Transgenic Models
Price, D. L., Tanzi, R. E., Borchelt, D. R., & Sisodia, S. S. (1998) · Annual Review of Genetics · doi:10.1146/annurev.genet.32.1.461 · Cited by 406
Apolipoprotein E in Alzheimer's Disease: An Update
Yu, J.-T., Tan, L., & Hardy, J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014300 · Cited by 394
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
Gomez‐Isla, T., West, H. L., Rebeck, G. W., Harr, S. D., Growdon, J. H., Locascio, J. J., Perls, T. T., Lipsitz, L. A., & Hyman, B. T. (1996) · Annals of Neurology · doi:10.1002/ana.410390110 · Cited by 378
Apolipoprotein E: an important gene and protein to follow in laboratory medicine
Siest, G., Pillot, T., Régis-Bailly, A., Leininger-Muller, B., Steinmetz, J., Galteau, M. M., & Visvikis, S. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.8.1068 · Cited by 347
Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
Koffie, R. M., Hashimoto, T., Tai, H.-C., Kay, K. R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K. J., Frosch, M. P., Lee, V. M., et al. (2012) · Brain · doi:10.1093/brain/aws127 · Cited by 327
The Mechanisms of Action of Curcumin in Alzheimer’s Disease
Tang, M., & Taghibiglou, C. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170188 · Cited by 304
Early onset familial Alzheimer’s disease: Mutation frequency in 31 families
Janssen, J. C., Beck, J. A., Campbell, T. A., Dickinson, A., Fox, N. C., Harvey, R. J., Houlden, H., Rossor, M. N., & Collinge, J. (2003) · Neurology · doi:10.1212/01.wnl.0000042088.22694.e3 · Cited by 301
Self-citationMitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease
Albers, D. S., & Flint Beal, M. (2000) · Advances in Dementia Research · doi:10.1007/978-3-7091-6781-6_16 · Cited by 297
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285
“…is likely to be encoded at the protein coding polymorphism, it is likely that other genetic variability at this locus, probably altering APOE expression, also contributes to the risk of developing AD (Bekris et al., 2009; Chartier-Harlin et al., 1994; Lambert et al., 1997; Lambert et al., 2002).”
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Exploring the Etiology of Alzheimer Disease Using Molecular Genetics
Lendon, C. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340059034 · Cited by 273
Age-related macular degeneration (AMD): Alzheimer's disease in the eye?
Kaarniranta, K., Salminen, A., Haapasalo, A., Soininen, H., & Hiltunen, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101908 · Cited by 248
“In contrast to AMD, the APOE-ε4 polymorphism represents the strongest thus far identified risk factor for AD, whereas the APOE- ε2 allele carriers have a reduced risk for developing AD (http://www.alzgene.org) [53] [54] [55] [56] [57].”
BackgroundProtection against Alzheimer's disease with apoE ∈2
Talbot, C., Lendon, C., Craddock, N., Shears, S., Morris, J., & Goate, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92557-7 · Cited by 225
Laws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223
Plasma clusterin and the risk of Alzheimer disease
Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220
Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred
Pastor, P., Roe, C. M., Villegas, A., Bedoya, G., Chakraverty, S., García, G., Tirado, V., Norton, J., Ríos, S., Martínez, M., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10636 · Cited by 194
Cerebrovascular lesions induce transient -amyloid deposition
Garcia-Alloza, M., Gregory, J., Kuchibhotla, K. V., Fine, S., Wei, Y., Ayata, C., Frosch, M. P., Greenberg, S. M., & Bacskai, B. J. (2011) · Brain · doi:10.1093/brain/awr300 · Cited by 187
Seshadri, S. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540350068018 · Cited by 163
Why is the amyloid beta peptide of Alzheimer’s disease neurotoxic?
Rauk, A. (2008) · Dalton Transactions · doi:10.1039/b718601k · Cited by 139
ApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation
Sen, A., Nelson, T. J., & Alkon, D. L. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0260-15.2015 · Cited by 133
ApoE immunoreactivity and microglial cells in Alzheimer’s disease brain
Uchihara, T., Duyckaerts, C., He, Y., Kobayashi, K., Seilhean, D., Amouyel, P., & Hauw, J.-J. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11763-m · Cited by 131
Self-citationComplement receptor 1 (CR1) and Alzheimer's disease
Crehan, H., Holton, P., Wray, S., Pocock, J., Guerreiro, R., & Hardy, J. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.07.017 · Cited by 129
Implications of Glycosylation in Alzheimer’s Disease
Haukedal, H., & Freude, K. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.625348 · Cited by 114
Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods
Fonteh, A. N., Harrington, R. J., Huhmer, A. F., Biringer, R. G., Riggins, J. N., & Harrington, M. G. (2006) · Disease Markers · doi:10.1155/2006/202938 · Cited by 113
APOE is a major susceptibility gene for Alzheimer’s disease
Roses, A. D., & Saunders, A. M. (1994) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(94)90091-4 · Cited by 108
Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides
Ma, J., Brewer, H. B., & Potter, H. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00112-1 · Cited by 108
ApoE and Aβ1–42 Interactions: Effects of Isoform and Conformation on Structure and Function
Manelli, A. M., Stine, W. B., Van Eldik, L. J., & LaDu, M. J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:235 · Cited by 95
Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3
Rebeck, G. W., Kindy, M., & LaDu, M. J. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4304 · Cited by 89
Zhou, Q., Zhao, F., Lv, Z.-P., Zheng, C.-G., Zheng, W.-D., Sun, L., Wang, N.-N., Pang, S., de Andrade, F. M., Fu, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087017 · Cited by 76
Yang, D.-S., Small, D. H., Seydel, U., Smith, J. D., Hallmayer, J., Gandy, S. E., & Martins, R. N. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00561-2 · Cited by 76
Tsuang, D., Kukull, W., Sheppard, L., Barnhart, R. L., Peskind, E., Edland, S. D., Schellenberg, G., Raskind, M., & Larson, E. B. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb01836.x · Cited by 69
Park, J.-C., Han, S.-H., Cho, H. J., Byun, M. S., Yi, D., Choe, Y. M., Kang, S., Jung, E. S., Won, S. J., Kim, E. H., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0248-8 · Cited by 63
Genetic variation in APOE cluster region and Alzheimer's disease risk
Cervantes, S., Samaranch, L., Vidal-Taboada, J. M., Lamet, I., Bullido, M. J., Frank-García, A., Coria, F., Lleó, A., Clarimón, J., Lorenzo, E., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.023 · Cited by 62
Roher, A. E., Garami, Z., Alexandrov, A. V., Kokjohn, T. A., Esh, C. L., Kalback, W. M., Vedders, L. J., Wilson, J. R., Sabbagh, M. N., & Beach, T. G. (2006) · Neurological Research · doi:10.1179/016164106x130470 · Cited by 56
A subset of senile dementia with high incidence of the apolipoprotein E ϵ2 allele
Ikeda, K., Akiyama, H., Arai, T., Sahara, N., Mori, H., Usami, M., Sakata, M., Mizutani, T., Wakabayashi, K., & Takahashi, H. (1997) · Annals of Neurology · doi:10.1002/ana.410410522 · Cited by 55
Effect of APOE genotype and promoter polymorphism on risk of Alzheimer’s disease
Wang, J. C., Kwon, J. M., Shah, P., Morris, J. C., & Goate, A. (2000) · Neurology · doi:10.1212/wnl.55.11.1644 · Cited by 49
Human apolipoprotein C-I expression in mice impairs learning and memory functions
Abildayeva, K., Berbée, J. F. P., Blokland, A., Jansen, P. J., Hoek, F. J., Meijer, O., Lütjohann, D., Gautier, T., Pillot, T., De Vente, J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700518-jlr200 · Cited by 39
Chaudhry, A., & Rizig, M. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117270 · Cited by 37
Chen, Q., Peng, X. D., Huang, C. Q., Hu, X. Y., & Zhang, X. M. (2015) · Genetics and Molecular Research · doi:10.4238/2015.december.23.39 · Cited by 37
Thy1-ApoE4/C/EBPβ double transgenic mice act as a sporadic model with Alzheimer’s disease
Qian, Z., Wang, Z., Li, B., Meng, X., Kuang, Z., Li, Y., Yang, Y., & Ye, K. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02565-x · Cited by 28
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
Apolipoproteins E and C1 and brain morphology in memory impaired elders
Serra-Grabulosa, J. M., Salgado-Pineda, P., Junqué, C., Solé-Padullés, C., Moral, P., López-Alomar, A., López, T., López-Guillén, A., Bargalló, N., Mercader, J. M., et al. (2003) · Neurogenetics · doi:10.1007/s10048-002-0142-8 · Cited by 26
Prasinou, P., Dafnis, I., Giacometti, G., Ferreri, C., Chroni, A., & Chatgilialoglu, C. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.07.001 · Cited by 15
KAPLITT, M., GOURAS, G. K., MAKIMURA, H., JOVANOVIC, J., SWEENEY, D., GREENGARD, P., RELKIN, N. R., & GANDY, S. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32597.x · Cited by 12
E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles
Lendon, C. L., Martinez, A., Behrens, I. M., Kosik, K. S., Madrigal, L., Norton, J., Neuman, R., Myers, A., Busfield, F., Wragg, M., et al. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)10:3
Metadata
- Authors
- Chartier-Hariln, M.-C., Parfitt, M., Legrain, S., Pérez-Tur, J., Brousseau, T., Evans, A., Berr, C., Vldal, O., Roques, P., Gourlet, V., Fruchart, J.-C., Delacourte, A., Rossor, M., & Amouyel, P.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 1994
- Volume
- 3
- Issue
- 4
- Pages
- 569-574
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2145838320
- Cited by
- 438
- References
- 0
- FWCI
- 20.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.